Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended					3 Months Ended		6 Months Ended				6 Months Ended		3 Months Ended		6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011	May 31, 2012	Dec. 31, 2011	Jun. 30, 2012 held outside of the United States	Jun. 30, 2012 Top Two Suppliers	Jun. 30, 2011 Top Two Suppliers	Jun. 30, 2012 Top Two Suppliers	Jun. 30, 2011 Top Two Suppliers	Jan. 31, 2012 Insurance	Jun. 30, 2012 Letter of Credit	Jun. 30, 2012 Clinical	Dec. 31, 2011 Clinical	Jun. 30, 2012 ResponseDX	Jun. 30, 2011 ResponseDX	Jun. 30, 2012 ResponseDX	Jun. 30, 2011 ResponseDX	Dec. 31, 2011 ResponseDX
Significant Accounting Policies [Line Items]
Payment period from the date of invoice														45 days
Accounts receivable	$ 4,022,555		$ 4,022,555			$ 4,047,059								$ 1,257,526	$ 1,701,837	$ 2,765,029		$ 2,765,029		$ 2,345,222
Bad debt expense			307,265	299,931												51,340	159,713	307,265	299,931
Amortization period of software development costs	3 years		3 years
Line of credit agreement date			Jul. 04, 2011
Line of credit, maximum borrowing capacity	3,000,000		3,000,000										500,000
Line of credit, available borrowing base amount	1,178,264		1,178,264
Line of credit, borrowing base percentage of pharmaceutical accounts receivable	80.00%		80.00%
Line of credit borrowing base, age of pharmaceutical accounts receivable	90 days		90 days
Line of credit, interest above prime rate			1.00%
Line of credit, interest charged			5.00%
Line of credit, amount drawn	1,000,000		1,000,000			1,000,000
Bank line of credit, over-advance amount required to be repaid					298,000
Advertising costs	4,090	16,595	12,971	66,477
Insurance coverage per depositor at each financial institution												250,000
Cash							$ 9,895
Percentage of total purchase, by supplier								69.00%	84.00%	69.00%	75.00%